HeartFlow expects FDA go-ahead for imaging-based FFR software any day now
This article was originally published in Clinica
Executive Summary
HeartFlow is expecting US FDA approval for its computed tomography-based coronary fractional flow reserve software (FFRCT) very soon, and a US launch will follow straight after. The firm plans to start with around half a dozen sites, CEO John Stevens told Clinica’s sister publication The Gray Sheet.